Stay updated on Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial

Sign up to get notified when there's something new on the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    Added Fallopian tube cancer to the listed conditions and introduced the Genetic and Rare Diseases Information Center as a resource; updated page revision from v3.4.1 to v3.4.2.
    Difference
    0.2%
    Check dated 2026-02-14T12:32:44.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    Site revision updated from v3.4.0 to v3.4.1, indicating a minor platform update. This change does not affect study content or page layout; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-07T07:35:08.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The changes include showing the glossary, capitalizing the QC criteria label from 'Last Update Submitted that met QC Criteria' to 'Last Update Submitted that Met QC Criteria', updating 'No FEAR Act Data' wording, and adding 'Revision: v3.4.0', while removing the older label and 'Revision: v3.3.4'.
    Difference
    0.2%
    Check dated 2026-01-24T02:06:50.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The page shows a revision update from v3.3.3 to v3.3.4, which is a metadata/version change and does not alter study content or data. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-17T00:32:39.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    Added a Locations section with Massachusetts sites and included Massachusetts in the site listings. Removed the HHS Vulnerability Disclosure and updated the page revision to v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-19T10:44:38.000Z thumbnail image
  7. Check
    89 days ago
    Change Detected
    Summary
    The page shows Revision: v3.3.2, replacing Revision: v3.3.1. No study content or critical functionality is affected.
    Difference
    0.0%
    Check dated 2025-11-28T00:35:56.000Z thumbnail image

Stay in the know with updates to Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page.